» Articles » PMID: 35372009

Prognostic Factors in Stage IV Colorectal Cancer Patients With Resection of Liver And/or Pulmonary Metastases: A Population-Based Cohort Study

Overview
Journal Front Oncol
Specialty Oncology
Date 2022 Apr 4
PMID 35372009
Authors
Affiliations
Soon will be listed here.
Abstract

Importance: Currently, surgical resection of distant metastatic lesions has become the preferred treatment for select colorectal cancer (CRC) patients with liver metastasis (LM) and/or pulmonary metastasis (PM). Metastasectomy is the most common curative method. However, evidence of the factors affecting the prognosis of CRC patients after resection of LM and/or PM is still insufficient.

Objective: To explore the prognostic factors of CRC patients with LM and/or PM who have undergone resection of metastatic tumors and to provide reliable selection factors for surgical treatment in patients affected by LM and/or PM from CRC.

Methods: The SEER database was used to identify eligible CRC LM and/or PM patients who underwent resection of the primary tumor and distant metastases from January 1, 2010, to December 31, 2018. The Kaplan-Meier method was used to calculate survival, and comparisons were performed using the log-rank test for univariate analysis. A Cox proportional hazards regression model was used to identify prognostic factors for the multivariate analysis. The outcomes included overall survival (OS) and cancer-specific survival (CSS).

Results: A total of 3,003 eligible colorectal cancer patients with LM and/or PM were included in this study. The 3-year and 5-year OS rates were 53% and 33.6%, respectively, and the 3-year and 5-year CSS rates were 54.2% and 35.3%, respectively. In the adjusted multivariate analysis, age < 65 years (OS: p=0.002, CSS: p=0.002) was associated with better long-term outcomes, and primary tumors located on the left side of the colon (OS: p=0.004, CSS: p=0.006) or rectum (OS: p=0.004, CSS: p=0.006), T3 stage (OS: p<0.001, CSS: p<0.001), number of regional lymph nodes examined ≥ 12 (OS: p<0.001, CSS: p=0.001), and CRC LM (OS: p<0.001, CSS: p<0.001) were positive prognostic factors for survival after resection of metastatic tumors.

Conclusion: Age < 65 years is associated with better long-term outcomes in colorectal cancer patients with LM and/or PM, analogously to the left sided primary tumor, T3 stage, number of regional lymph nodes examined ≥ 12 and liver metastases.

Citing Articles

Non-small cell lung cancer detection through knowledge distillation approach with teaching assistant.

Pavel M, Islam R, Babor S, Mehadi R, Khan R PLoS One. 2024; 19(11):e0306441.

PMID: 39504338 PMC: 11540227. DOI: 10.1371/journal.pone.0306441.


The Efficacy and Safety of Anlotinib Plus Etoposide with Cisplatin/Carboplatin in the First-Line Treatment of Lung Cancer: A Phase II Clinical Study.

Lv X, Liu Y, Feng Y, Liang H, Zhi W J Cancer. 2024; 15(11):3539-3546.

PMID: 38817880 PMC: 11134448. DOI: 10.7150/jca.91701.


A Glimpse into the Role and Effectiveness of Splenectomy for Isolated Metachronous Spleen Metastasis of Colorectal Cancer Origin: Long-Term Survivals Can Be Achieved.

Tivadar B, Dumitrascu T, Vasilescu C J Clin Med. 2024; 13(8).

PMID: 38673636 PMC: 11050850. DOI: 10.3390/jcm13082362.


Role of long non-coding RNA ELFN1-AS1 in carcinogenesis.

HajiEsmailPoor Z, Fayazi A, Teymouri M, Tabnak P Discov Oncol. 2024; 15(1):74.

PMID: 38478184 PMC: 10937879. DOI: 10.1007/s12672-024-00929-x.


Synergistic impact of Gui Zhi Shao Yao Zhi Mu Decoction and leflunomide on gut microbiota in rheumatoid arthritis: insights from 16S rDNA sequencing.

Sun Y, Chen X, Zhang Y, Chen X, Zhang C, Zhao J Am J Transl Res. 2024; 16(2):654-668.

PMID: 38463585 PMC: 10918140.


References
1.
Nardo B, Serafini S, Ruggiero M, Grande R, Fugetto F, Zullo A . Liver resection for metastases from colorectal cancer in very elderly patients: New surgical horizons. Int J Surg. 2016; 33 Suppl 1:S135-41. DOI: 10.1016/j.ijsu.2016.06.014. View

2.
Tsilimigras D, Sahara K, Hyer J, Diaz A, Moris D, Bagante F . Trends and outcomes of simultaneous versus staged resection of synchronous colorectal cancer and colorectal liver metastases. Surgery. 2021; 170(1):160-166. DOI: 10.1016/j.surg.2021.01.041. View

3.
Heinemann V, Fischer von Weikersthal L, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran S . FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol. 2014; 15(10):1065-75. DOI: 10.1016/S1470-2045(14)70330-4. View

4.
Nanji S, Tsang M, Wei X, Booth C . Regional lymph node involvement in patients undergoing liver resection for colorectal cancer metastases. Eur J Surg Oncol. 2017; 43(2):322-329. DOI: 10.1016/j.ejso.2016.10.033. View

5.
Gonzalez M, Poncet A, Combescure C, Robert J, Ris H, Gervaz P . Risk factors for survival after lung metastasectomy in colorectal cancer patients: a systematic review and meta-analysis. Ann Surg Oncol. 2012; 20(2):572-9. DOI: 10.1245/s10434-012-2726-3. View